Treats migraine. Sold as Vyepti. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Eptinezumab-Jjmr (sold as Vyepti), first approved Feb 21, 2020, with 2 new uses approved and 0 published complete response letters.
| Vyepti | Part B | $107M | +52% | 8,418 |
| Vyepti | Part D | $25.1M | +67% | 2,188 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Feb 21, 2020 | VyeptiBLA 761119 · New molecular entity | Lundbeck Seattle BioPharmaceuticals, Inc. | 7 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
